The online version of this article (doi:10.1186/1477-7819-10-1) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
SN is a main conductor of this study, participated in the design of the study, and drafted the manuscript. NT, TK, SM and KN participated in the acquisition of data. TO, HT, MS, TI, YH, and SS participated in the collection of materials and data of the study. TH designed and organized the study, and wrote the manuscript. HN was in charge of the histopathological assessment. All authors read and approved the final manuscript.
To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa).
Complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m2) with estramustine phosphate (560 mg) were given to 18 PCa patients before radical prostatectomy. Subsequently, the clinical and pathological outcomes were analyzed.
No patients had severe adverse events during chemohormonal therapy, and hence they were treated with radical prostatectomy. Two patients (11.1%) achieved pathological complete response. Surgical margins were negative in all patients. At a median follow-up of 18 months, 14 patients (77.8%) were disease-free without PSA recurrence. All 4 patients with PSA recurrence had pathologic T3b or T4 disease and 3 of these 4 patients had pathologic N1 disease.
We found that neoadjuvant chemohormonal therapy with complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy was safe, feasible, and associated with favorable pathological outcomes in patients with a high risk of localized PCa.
Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC: What are the outcomes of radical prostatectomy for high-risk prostate cancer?. Urology. 76: 710-714.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998, 280: 969-974. 10.1001/jama.280.11.969. CrossRefPubMed
Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK: Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005, 11: 5233-5240. 10.1158/1078-0432.CCR-05-0299. CrossRefPubMed
Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P: Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007, 100: 274-280. 10.1111/j.1464-410X.2007.06760.x. CrossRefPubMed
Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME: Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008, 180: 565-570. 10.1016/j.juro.2008.04.012. discussion 570 CrossRefPubMed
Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A: Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009, 101: 1248-1252. 10.1038/sj.bjc.6605320. PubMedCentralCrossRefPubMed
Miyake H, Fujimoto H, Komiyama M, Fujisawa M: Development of "extended radical retropubic prostatectomy": a surgical technique for improving margin positive rates in prostate cancer. Eur J Surg Oncol. 36: 281-286.
Freiha FS, Salzman J: Surgical staging of prostatic cancer: transperitoneal versus extraperitoneal lymphadenectomy. J Urol. 1977, 118: 616-617. PubMed
pathology JUAtJso: General rule for clinical and pathological studies on prostate cancer. 2010, Tokyo: Kanehara, 4
Franke RM, Carducci MA, Rudek MA, Baker SD, Sparreboom A: Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol. 28: 4562-4567.
- Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II